NanoViricides Inc. - NNVC STOCK NEWS

NanoViricides files Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023. The report shows a cash and cash equivalent current assets balance of approximately $9.9 Million, a decrease from $11.5 Million in December 2022. The Company entered into a License Agreement with Karveer Meditech, Pvt. Ltd., India, for the use, sale, or offer of sale in India of its two clinical test drug candidates. NV-CoV-2, the Company's lead drug candidate, is about to enter Phase Ia/Ib human clinical trials. The Company estimates it has sufficient funds to complete the trials. NV-CoV-2 is a broad-spectrum, pan-coronavirus drug for the treatment of COVID. The Company also highlights the potential of its drug candidate NV-387 to have a significantly broader spectrum of antiviral effectiveness than the coronavirus family alone.

NanoViricides, Inc. will be presenting at The Inaugural EF Hutton Global Conference on May 10-11, 2023 in New York City. The conference provides an opportunity for key executives to share their stories with investors and press.

NanoViricides, Inc. (NNVC) is advancing its antiviral drug candidate NV-387, originally developed for COVID-19, to explore broader applications against various viral infections. Pre-clinical studies show NV-387 exhibits activity against seasonal coronaviruses and SARS-CoV-2, aiming to serve as a broad-spectrum antiviral agent. The drug targets virus particles similarly to antibiotics targeting bacteria, with potential effectiveness against viruses like RSV and others. After successful Phase 1 trials, NV-387 could enter Phase 2 trials for multiple viral diseases, potentially optimizing development costs. Currently, the company is also focusing on therapeutics for the poxvirus family and other respiratory viruses, addressing the unmet need for safe and effective antiviral treatments.

NanoViricides, Inc. (NYSE American: NNVC) announced the shipment of drug products for the clinical trials of NV-CoV-2, its COVID-19 drug candidate, to collaborator Karveer Meditech Pvt. Ltd. in India. Karveer has secured regulatory approvals to conduct these trials, which are expected to start soon. NV-CoV-2 is designed to target SARS-CoV-2 and its evolving variants and has shown broad-spectrum efficacy and strong safety in preclinical studies. The drug will be available in oral syrup and gummies, as well as injectable and infusion forms for various patient populations. Unlike current antiviral treatments, NV-CoV-2 aims to treat all segments of the population, addressing unmet medical needs in the ongoing COVID-19 pandemic.

NanoViricides has signed a License Agreement with Karveer Meditech Pvt. Ltd. for the commercialization of its COVID drugs NV-CoV-2 and NV-CoV-2-R in India. Karveer will oversee the clinical development and has reportedly obtained necessary regulatory permissions. The human clinical trials are anticipated to commence shortly. Under the agreement, Karveer will conduct evaluations in compliance with local regulations, while NanoViricides retains rights to the data generated. Upon commercialization, NanoViricides will earn a 70% royalty on sales. This marks a significant milestone for the company in advancing its antiviral therapies.

NanoViricides, Inc. (NYSE American: NNVC) filed its Quarterly Report on Form 10-Q for Q1 FY2023 ending December 31, 2022, on February 14, 2023. The company reported cash and equivalents of approximately $11.5 million and $8.4 million in Property and Equipment. Liabilities stood at $0.46 million. The company anticipates higher cash expenditures as clinical trials for its lead drug candidate NV-CoV-2 for COVID-19 begin. NanoViricides has initiated the manufacture of clinical supply for NV-387 and expects to launch oral formulations for COVID-19 treatment, preparing for trials to address unmet needs in antiviral therapies.

NanoViricides (NYSE Amer.:NNVC) will present at the Biotech Showcase™ 2023 Conference in San Francisco on January 9 at 10:30 am PT. Dr. Anil Diwan will discuss the Company’s lead drug candidate, NV-CoV-2, for COVID-19 treatment and its broad-spectrum antiviral platform. This presentation aims to foster partnerships for drug development. The conference, running from January 9-11 at the Hilton San Francisco, is a networking opportunity for life sciences investors and executives.

NanoViricides, Inc. (NYSE Amer. NNVC) announced that its President, Dr. Anil Diwan, will present at the RHK Capital Disruptive Growth Conference in New York City on December 6, 2022, at 1:20 PM ET. The presentation will be accessible via webcast at this link. Dr. Diwan will discuss the lead drug candidate, NV-CoV-2, aimed at treating COVID-19 and long COVID, emphasizing its potential effectiveness against emerging variants.
Furthermore, he will outline the company's pipeline for other viral diseases.

NanoViricides, Inc. (NNVC) filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022, reporting cash and cash equivalents of approximately $13.1 million and total current liabilities of $0.51 million. The company aims to commence clinical trials for its lead drug candidate NV-CoV-2, designed to treat COVID-19. The IND application is nearing completion, pending engagement with a Clinical Research Organization (CRO). NV-CoV-2 is expected to effectively address COVID-19 and variants due to its broad-spectrum capabilities.